Amniotic Membrane Transplant Session to be a Conference Highlight | ASRS 2025
A session on a surgery technique to treat macular holes using amniotic membrane transplants will be one of the highlights at the 2025 meeting of the American Society of Retina Specialists, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
One of the highlights at the 2025 meeting of the American Society of Retina Specialists will be a talk on amniotic membrane transplants for difficult-to-treat macular holes, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
This invited talk, called ‘Amniotic Membrane in Vitreoretinal Surgery: When and How,’ will be hosted by Stanislao Rizzo, M.D., chair of the ophthalmology unit, Agostino Gemelli University Hospital Foundation, Rome, Italy.
“This technique involves putting tissue either on top of the retina or underneath the retina to fix difficult macular holes, especially in patients who are nearsighted,” Shah said in a recent video interview with Managed Healthcare Executive.
Gaurav K. Shah, M.D.
Nearsightedness has become increasingly common in Asia, where myopia rates have risen to 80 to 90% in countries including South Korea and Japan.
“The world is going to be pathologically myopic,” Shah said.
The 43rd annual ASRS takes place from July 30 to August 2, 2025, at the Long Beach Convention Center in Long Beach, California.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
First-in-Class Therapy for Diabetic Retinopathy Shows Six-Month Benefit | ASRS 2025
July 31st 2025PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block endothelin signaling to increase ocular blood flow and prevent vision loss.
Read More
Changes to Susvimo Port Delivery System Explained | ASRS 2024
July 31st 2025Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.
Read More
Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.
Read More
